Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT04071223 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | active not recruiting | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04235777 | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT07180212 | Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer | active not recruiting | N/A | 360 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00745355 | Quality of Life in Patients With Bladder Cancer | active not recruiting | — | 550 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 235 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)(SunRISe-3) | active not recruiting | Phase 3 | 1,135 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT04963153 | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT02968732 | Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder | active not recruiting | N/A | 65 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03635892 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | active not recruiting | Phase 2 | 81 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT05080998 | Longitudinal Bladder Cancer Study for Tumour Recurrence(LOBSTER) | active not recruiting | — | 450 | Pacific Edge LimitedINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT05252585 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | active not recruiting | Phase 4 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | RenJi HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05889195 | Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria(microDRIVE) | active not recruiting | — | 1,000 | Pacific Edge LimitedINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05538663 | Intravesical BCG vs GEMDOCE in NMIBC(BRIDGE) | active not recruiting | Phase 3 | 870 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05863351 | Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | active not recruiting | Phase 3 | 472 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07821177 | Bladder Preservation or Cystectomy for MIBC | active not recruiting | Early Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02812420 | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery | active not recruiting | Early Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05012371 | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT07527637 | Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer | active not recruiting | — | 40,000 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT06708949 | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06480565 | A Phase 1/2 Trial of ADI-270 in ccRCC | active not recruiting | Phase 1 / Phase 2 | 60 | Adicet TherapeuticsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00365157 | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | active not recruiting | Phase 1 / Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01480154 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07148765 | Use of Wearables Following Cystectomy- Part II | active not recruiting | N/A | 50 | University of PittsburghOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04707248 | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | active not recruiting | Phase 1 | 179 | Daiichi SankyoINDUSTRY | 2 | Sep 4, 2026 | clinicaltrials |
| NCT02978118 | Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers) | active not recruiting | — | 67 | Duke UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | active not recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04917809 | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05704244 | Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) | active not recruiting | Phase 3 | 25 | Ferring PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06745609 | Prehabilitation Prior to Surgery for Kidney Tumors(Pre-KiT) | active not recruiting | N/A | 60 | Herlev and Gentofte HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03647878 | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.(CABOCARE) | active not recruiting | — | 224 | IpsenINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials